Terms: = Sarcomas AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
428 results:
1. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
[TBL] [Abstract] [Full Text] [Related]
2. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.
Wang Y; Ma X; Xu E; Huang Z; Yang C; Zhu K; Dong Y; Zhang C
Clin Transl Med; 2024 Feb; 14(2):e1586. PubMed ID: 38372422
[TBL] [Abstract] [Full Text] [Related]
3. Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo.
Kong Y; Li X; Zhang H; Fu B; Jiang HY; Yang HL; Dai J
Cell Death Dis; 2024 Jan; 15(1):57. PubMed ID: 38228583
[TBL] [Abstract] [Full Text] [Related]
4. Soy isoflavones induces mitophagy to inhibit the progression of osteosarcoma by blocking the AKT/mtor signaling pathway.
Zheng Z; Zhao X; Yuan B; Jiang S; Yan R; Dong X; Yao Q; Liang H
Mol Med; 2024 Jan; 30(1):5. PubMed ID: 38191316
[TBL] [Abstract] [Full Text] [Related]
5. Solute carrier family 35 member A2 regulates mitophagy through the PI3K/AKT/mtor axis, promoting the proliferation, migration, and invasion of osteosarcoma cells.
Luo X; Zhang J; Guo C; Jiang N; Zhang F; Jiao Q; Xu K; Yang J; Qu G; Lv XB; Zhang Z
Gene; 2024 Mar; 898():148110. PubMed ID: 38151177
[TBL] [Abstract] [Full Text] [Related]
6. Phase I Study of mtorC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mtor/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
7. Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database.
Mochizuki T; Ikegami M; Akiyama T
Cancer Sci; 2024 Feb; 115(2):575-588. PubMed ID: 38115234
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
9. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study.
Phadnis S; Wang X; Daw NC; Herzog CE; Subbiah IM; Zaky W; Gouda MA; Morani AC; Amini B; Harrison DJ; Piha-Paul SA; Meric-Bernstam F; Gorlick R; Schwartz CL; Subbiah V
ESMO Open; 2023 Dec; 8(6):101609. PubMed ID: 37879233
[TBL] [Abstract] [Full Text] [Related]
10. Epilepsy in gliomas: recent insights into risk factors and molecular pathways.
Rudà R; Bruno F; Pellerino A
Curr Opin Neurol; 2023 Dec; 36(6):557-563. PubMed ID: 37865836
[TBL] [Abstract] [Full Text] [Related]
11. RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/AKT/mtor pathway.
Wei Z; Xia K; Zheng D; Gong C; Guo W
Mol Med; 2023 Oct; 29(1):133. PubMed ID: 37789274
[TBL] [Abstract] [Full Text] [Related]
12. Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mtor pathway.
Sim I; Choe W; Ri J; Su H; Moqbel SAA; Yan W
Med Oncol; 2023 Sep; 40(10):294. PubMed ID: 37668818
[TBL] [Abstract] [Full Text] [Related]
13. The Targeted Therapies for Osteosarcoma
Wang S; Ren Q; Li G; Zhao X; Zhao X; Zhang Z
Curr Mol Pharmacol; 2024; 17(1):e210823220109. PubMed ID: 37602543
[TBL] [Abstract] [Full Text] [Related]
14. Histological response to radiotherapy is an early event in myxoid liposarcoma.
Lam SW; Silva TM; Traast-Kooistra J; Bruijn IB; van den Akker B; Bakker PAC; Lansu J; Haas RLM; Bovée JVMG
Virchows Arch; 2023 Oct; 483(4):487-495. PubMed ID: 37572156
[TBL] [Abstract] [Full Text] [Related]
15. Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.
Nirala BK; Yamamichi T; Yustein JT
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511127
[TBL] [Abstract] [Full Text] [Related]
16. Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mtor/HIF-1α/VEGF and EMT signalling pathways.
Zeng X; Liu S; Yang H; Jia M; Liu W; Zhu W
J Pharm Pharmacol; 2023 Nov; 75(11):1405-1417. PubMed ID: 37498992
[TBL] [Abstract] [Full Text] [Related]
17. Systemic treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis.
Testa S; Bui NQ; Ganjoo KN
Cancer Res Commun; 2023 Jul; 3(7):1212-1223. PubMed ID: 37448552
[TBL] [Abstract] [Full Text] [Related]
18. Targeting Autophagy With the Synergistic Combination of Chloroquine and Rapamycin as a Novel Effective treatment for Well-differentiated Liposarcoma.
Masaki N; Aoki Y; Obara K; Kubota Y; Bouvet M; Miyazaki J; Hoffman RM
Cancer Genomics Proteomics; 2023; 20(4):317-322. PubMed ID: 37400145
[TBL] [Abstract] [Full Text] [Related]
19. LncRNA-HOTAIRM1 promotes aerobic glycolysis and proliferation in osteosarcoma via the miR-664b-3p/Rheb/mtor pathway.
Yu X; Duan W; Wu F; Yang D; Wang X; Wu J; Zhou D; Shen Y
Cancer Sci; 2023 Sep; 114(9):3537-3552. PubMed ID: 37316683
[TBL] [Abstract] [Full Text] [Related]
20. New targeted treatments for advanced sarcomas.
Li CC; Chen TW
Curr Opin Oncol; 2023 Jul; 35(4):309-314. PubMed ID: 37222206
[TBL] [Abstract] [Full Text] [Related]
[Next]
